Neuropathic Pain
Conditions
Brief summary
The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To describe the pharmacokinetics (PK) of BIIB074 and its known metabolites and the disposition profiles of total radioactivity in whole blood and plasma following a single oral dose. The secondary objectives of this study are: To assess the safety and tolerability of BIIB074 in healthy participants and To identify and characterize any additional metabolites of BIIB074 in plasma, urine, and feces.
Interventions
DRUGBIIB074
Administered orally as specified in treatment arm
Sponsors
Biogen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * All subjects must practice effective contraception during the study and be willing and able to continue contraception for 90 days after the administration of study treatment. * Must be in good health as determined by the Investigator, based on medical history and screening evaluations. Key
Exclusion criteria
* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator. * Previous exposure to BIIB074. * Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the subject unsuitable for enrollment. NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Terminal elimination half-life (t1/2) | 2 hours post dose up to Day 9 |
| Cumulative percentage of BIIB074 dose excreted (Cum %Feu) | 12 hours prior to dosing up to Day 9 |
| Maximum observed concentration (Cmax) | 2 hours post dose up to Day 9 |
| Time to reach Cmax (Tmax) | 2 hours post dose up to Day 9 |
| Area under the concentration-time curve from time 0 to time of the last measurable drug concentration (AUC0-t) | 2 hours post dose up to Day 9 |
| Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) | 2 hours post dose up to Day 9 |
| Apparent total body clearance (CL/F) | 2 hours post dose up to Day 9 |
| Apparent volume of distribution (Vd/F) | 2 hours post dose up to Day 9 |
| Renal clearance (CLR) | 2 hours post dose up to Day 9 |
| Metabolite-to-parent ratio at Cmax (MRCmax) | 2 hours post dose up to Day 9 |
| Metabolite-to-parent ratio in AUC (MRAUC) | 2 hours post dose up to Day 9 |
| Urinary amount excreted per sampling interval (Aeu) | 12 hours prior to dosing up to Day 9 |
| Fecal amount excreted per sampling interval (Aef) | Prior to dosing up to Day 9 |
| Cumulative urinary amount excreted per sampling interval (Cum Aeu) | 12 hours prior to dosing up to Day 9 |
| Cumulative fecal amount excreted per sampling interval (Cum Aef) | Prior to dosing up to Day 9 |
| Percentage of radioactive urinary dose excreted per sampling interval (%Feu) | 12 hours prior to dosing up to Day 9 |
| Percentage of radioactive fecal dose excreted per sampling interval (%Fef) | Prior to dosing up to Day 9 |
| Cumulative percentage of radioactive urinary dose excreted per sampling interval (Cum %Feu) | 12 hours prior to dosing up to Day 9 |
| Cumulative percentage of radioactive fecal dose excreted per sampling interval (Cum %Fef) | Prior to dosing up to Day 9 |
| Urinary amount of BIIB074 and its known metabolites excreted per sampling interval (Aeu) | 12 hours prior to dosing up to Day 9 |
| Cumulative urinary amount of BIIB074 and its known metabolites excreted per sampling interval (Cum Aeu) | 12 hours prior to dosing up to Day 9 |
| Percentage of BIIB074 dose excreted per sampling interval (%Feu) | 12 hours prior to dosing up to Day 9 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with clinically significant vital sign abnormalities | Up to Day 9 |
| Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities | Up to Day 9 |
| Number of participants with clinically significant laboratory assessment abnormalities | Up to Day 9 |
| Radioactivity profiles in plasma, urine and feces | Up to Day 9 |
| Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs) | Up to Day 9 |
Countries
United States
Outcome results
None listed